Celea Therapeutics has dosed the first patient in SURPASS-IPF, a global Phase 3 trial evaluating deupirfenidone against pirfenidone in approximately 1,100 adults with idiopathic pulmonary fibrosis across more than 30 countries. The pivotal study will measure whether the investigational antifibrotic can deliver superior preservation of lung function over 52 weeks, with topline results expected during the second half of 2029.
This is more than an operational milestone marking the transition from planning to execution. Celea is undertaking a direct superiority trial against an approved treatment, creating a substantially higher evidentiary hurdle than a conventional placebo-controlled study designed only to show that an experimental therapy works better than no active treatment.
The decision reflects confidence generated by the Phase 2b ELEVATE IPF trial, but it also exposes the program to a more definitive test. The earlier study produced an encouraging signal over 26 weeks, while SURPASS-IPF must reproduce and extend that signal across a much larger, more geographically diverse population for twice as long.
The Phase 3 launch follows Celea’s $180 million financing completed in early July 2026. That transaction established the company as an independently financed PureTech Health-founded business, while giving it the capital required to begin a lengthy global program involving hundreds of clinical sites and a multiyear data collection period.
Why does SURPASS-IPF set a higher clinical hurdle than a typical placebo-controlled Phase 3 trial?
SURPASS-IPF will compare deupirfenidone at 825 mg three times daily with pirfenidone at 801 mg three times daily. Participants will not receive background antifibrotic therapy, and the trial does not include a placebo group, ensuring that everyone enrolled receives an active treatment.
The primary endpoint is the change from baseline in absolute forced vital capacity at week 52. Forced vital capacity measures the amount of air a person can forcibly exhale after a full inhalation and is widely used to assess the progression of idiopathic pulmonary fibrosis. Declining forced vital capacity reflects the continuing loss of functioning lung tissue as fibrosis advances.
A head-to-head superiority design gives clinicians and regulators a more practical comparison than a placebo-controlled study. If deupirfenidone produces a statistically persuasive and clinically relevant advantage over pirfenidone, the result would support a clearer treatment proposition than evidence showing only that the drug is effective against placebo.
The trade-off is risk. Pirfenidone already slows lung function decline, so the difference between the two active arms may be considerably smaller than the difference between either treatment and placebo. Variability in forced vital capacity measurements, treatment adherence, discontinuations and regional clinical practices can make that smaller difference harder to detect, even with approximately 1,100 participants.
The endpoint also measures lung physiology rather than survival, acute exacerbations or improvements in daily functioning. A successful statistical result will therefore be examined alongside the absolute size of the benefit, tolerability, treatment persistence and any supportive patient-reported or clinical outcomes.
How much confidence should the Phase 2b ELEVATE IPF results carry into the larger pivotal study?
ELEVATE IPF enrolled 257 participants who were assigned to deupirfenidone at 550 mg or 825 mg three times daily, pirfenidone at 801 mg three times daily, or placebo. The primary analysis combined the two deupirfenidone dose groups and compared them with placebo over 26 weeks.
In the high-dose deupirfenidone arm, the adjusted mean decline in forced vital capacity was 21.5 millilitres, compared with 112.5 millilitres for placebo. The resulting adjusted difference of 91 millilitres reached statistical significance. The pirfenidone arm recorded a 51.6-millilitre decline, providing a numerical reference for the dose selected for Phase 3.
Those data justified further development, but they did not settle the question SURPASS-IPF is designed to answer. The Phase 2b study was not primarily powered to establish definitive superiority of the 825 mg deupirfenidone dose over pirfenidone. Each individual treatment group was also relatively small, leaving the estimates more vulnerable to baseline imbalances, participant variability and chance.
The ongoing open-label extension has suggested that preservation of lung function may persist through at least 52 weeks. However, extension studies carry different interpretive limitations because participants who tolerate and complete the controlled portion are more likely to continue. The absence of a continuing randomized placebo or active control comparison makes the extension useful for durability and safety monitoring, but not a substitute for pivotal evidence.
The most credible interpretation is that ELEVATE IPF earned deupirfenidone the right to ask a much larger superiority question. It did not answer that question in advance. SURPASS-IPF must now demonstrate that the earlier numerical separation can survive a longer treatment period, a larger population and the operational complexity of more than 30 countries.
What does deuterating pirfenidone change, and can that produce a meaningful clinical advantage?
Deupirfenidone is a selectively deuterated form of pirfenidone. Three hydrogen atoms at a site involved in active metabolism are replaced with deuterium, a heavier and stable form of hydrogen. That modification is intended to slow metabolism while retaining pirfenidone’s established antifibrotic and anti-inflammatory activity.
The pharmacological proposition is relatively straightforward. Slower metabolism may increase exposure to the active parent drug and reduce relative exposure to its principal metabolite. This could allow patients to receive greater active-drug exposure without a corresponding increase in adverse effects.
In ELEVATE IPF, the 825 mg deupirfenidone dose produced approximately 50% greater drug exposure than 801 mg of pirfenidone, while the overall incidence of adverse events was broadly similar. Phase 1 research also found a lower frequency of gastrointestinal and nervous-system adverse events under certain deupirfenidone dosing conditions than with pirfenidone.
Those findings are encouraging because tolerability remains a practical limitation of antifibrotic treatment. Pirfenidone is associated with gastrointestinal effects, photosensitivity, rash and liver enzyme abnormalities. Dose reductions, interruptions and discontinuations can reduce real-world exposure to a medicine that must be taken continuously to slow a progressive disease.
Yet deupirfenidone does not eliminate the dosing burden in SURPASS-IPF. Both study drugs are administered three times daily. The Phase 3 advantage must therefore come from better efficacy, tolerability or treatment persistence rather than a simpler dosing schedule.
The decisive test will be whether higher exposure remains tolerable over 52 weeks in a much larger population. A drug that slows lung function decline more effectively but produces additional discontinuations may deliver less real-world value than its efficacy analysis initially suggests.
How will a 2029 readout compete in an IPF market that now has three approved US therapies?
The commercial environment facing deupirfenidone has changed since pirfenidone and nintedanib became the first United States-approved idiopathic pulmonary fibrosis treatments in 2014. The United States Food and Drug Administration approved nerandomilast in October 2025, introducing the first new treatment mechanism for the disease in more than a decade.
Nerandomilast is a preferential phosphodiesterase 4B inhibitor administered twice daily. Its approval means deupirfenidone would enter a market with three established options if it reaches regulators after the anticipated 2029 trial readout.
SURPASS-IPF does not directly compare deupirfenidone with nintedanib or nerandomilast. It also studies deupirfenidone as monotherapy rather than as an addition to existing antifibrotic treatment. Those design choices give the trial a clear regulatory question, but they will leave clinicians without randomized evidence showing how deupirfenidone performs against every major alternative or in combination-based treatment strategies.
Pricing and reimbursement could become equally important. Generic pirfenidone has been available in the United States since 2022, giving payers a lower-cost benchmark against which a newly approved deupirfenidone product would be assessed. A modest forced vital capacity difference without a persuasive tolerability or adherence advantage may not be enough to support preferred formulary positioning.
Conversely, a clinically meaningful superiority result could create a strong commercial case. Because deupirfenidone builds on a familiar antifibrotic foundation, pulmonologists may face a smaller conceptual adoption barrier than they would with an entirely unfamiliar mechanism. The advantage would still need to be sufficiently clear to justify switching stable patients or selecting the new product ahead of less expensive alternatives.
Why is the 505(b)(2) pathway strategically useful without making regulatory success automatic?
Celea’s United States strategy is built around the 505(b)(2) regulatory pathway. This route allows an application to rely partly on existing regulatory findings or published evidence involving an approved medicine while providing new data required for the modified product.
Following the end-of-Phase 2 discussion with the United States Food and Drug Administration, a successful SURPASS-IPF trial combined with the broader deupirfenidone evidence package could provide the clinical foundation required for a registration application. That creates a more focused development plan than conducting multiple independent Phase 3 trials.
The approach does not reduce the importance of the pivotal result. Celea must still show that deupirfenidone’s altered pharmacokinetic profile produces a favorable benefit-risk balance. Regulators will examine efficacy consistency, safety at higher exposure, metabolic differences, drug interactions, manufacturing controls and the adequacy of long-term follow-up.
The single-study strategy concentrates risk as well as capital. A clearly positive result could accelerate the route toward filing. An ambiguous result, unexpected safety imbalance or operational problem would leave the company with limited independent pivotal evidence to resolve uncertainty.
Does the $180 million financing materially reduce development risk for Celea and PureTech Health?
The financing removes one of the most immediate obstacles to trial initiation. Participants included RA Capital Management, Leaps by Bayer, PureTech Health, a United States healthcare-focused fund and a sovereign wealth fund. The syndicate gives Celea specialist financial backing as it moves from a PureTech-controlled program into an independently funded late-stage company.
PureTech Health plc retains a 35.4% fully diluted ownership interest in Celea, together with rights to tiered royalties, milestone payments and a share of sublicense income. That structure allows PureTech to retain meaningful exposure to deupirfenidone while reducing the amount of Phase 3 spending that must be carried directly on its own balance sheet.
PureTech shares closed at 120 pence in London on July 10, before the first-patient announcement. The stock was approximately 8.5% below its 50-day moving average and had declined about 8.5% over four weeks, while trading within a 52-week range of roughly 106 pence to 147 pence. That positioning suggests investor sentiment remained cautious despite the financing and approaching trial start.
The first patient milestone confirms that the capital has translated into execution, which may offer some sentiment support. It does not bring the principal value event much closer, however, because topline results remain more than three years away. PureTech investors are therefore receiving indirect exposure to a potentially valuable respiratory asset, but with dilution at the Celea level and a long period of clinical uncertainty.
For Celea, $180 million substantially improves operational visibility but should not be treated as eliminating financing risk. A 1,100-patient global Phase 3 trial, regulatory preparation, manufacturing scale-up and eventual commercial readiness represent a considerable multiyear commitment. Development delays or additional studies could increase capital requirements before the product generates revenue.
What milestones will show whether deupirfenidone remains on course before the 2029 results?
Enrollment will be the first major operational indicator. Recruiting approximately 1,100 people across more than 30 countries is demanding, particularly when eligible patients already have access to approved therapies. The requirement that participants not receive background antifibrotic treatment may further narrow the population willing and able to enter.
Retention will matter nearly as much as recruitment. Three-times-daily treatment for 52 weeks creates an adherence challenge in an older patient population that may have multiple health conditions and medications. Differences in discontinuation rates, dose intensity and missed doses could influence both the trial’s statistical power and the eventual commercial argument.
Safety updates, regulatory interactions and manufacturing progress will provide additional signals, although the blinded design may limit what can be disclosed before completion. Investigators and investors will also watch whether the competitive IPF pipeline produces new approvals or combination strategies before Celea reports its data.
The first patient dose starts the operational clock, but the program’s value will be determined by much more than completing enrollment. Celea has chosen a design that could produce unusually persuasive evidence if successful because deupirfenidone must beat an active standard rather than simply separate from placebo.
That same decision leaves little room for a merely respectable result. By 2029, a numerically modest advantage will be weighed against generic pirfenidone, nintedanib, nerandomilast and any additional therapies that reach the market. Deupirfenidone’s path to becoming a meaningful IPF treatment therefore depends on proving that its altered pharmacology delivers a benefit clinicians, patients and payers can see, not just a molecular difference they can describe.
